Short-Course Glecaprevir/Pibrentasvir Plus Ezetimibe Prevents HCV Transmission During Transplantation From HCV-Infected Donors

November 8-12, 2019; Boston, Massachusetts
This small study showed that a short preemptive course of GLE/PIB + EZE given pre- and post-transplant prevented HCV transmission in all HCV-uninfected patients who received organs from HCV-infected donors.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

Downloadable PDF resource from CCO on opioid use disorder treatment essentials for hepatologists and ID specialists managing HCV and/or HIV infection

Jenna Butner, MD Released: May 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue